Clinical Trials Directory

Trials / Completed

CompletedNCT04380714

Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19

Changes in the Consumption of Psychoactive Substances by People Incarcerated at the Villeneuve-Lès-Maguelone Prison During Containment Linked to COVID-19.

Status
Completed
Phase
Study type
Observational
Enrollment
700 (actual)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The SARS-CoV 2 pandemic started in China in December 2019, then reached France on January 24, 2020. On March 14, France moved into phase 3 of the epidemic threshold with the implementation of containment measures on March 17 Measures were put in place by N.Belloubet (French Minister of Justice) from March 17, including suspension of visiting rooms and activities in detention. Containment provides boredom and isolation with many potential consequences: sleep disturbance, anxiety, PTSD, depression, suicide, addictive behavior and violence. However,prisoners have a higher prevalence of substance use disorders than the general population. What will have been the impact of the confinement on the consumption of psychoactive substances by prisoners at the Villeneuve Les Maguelone prison. * Anonymous questionnaire from the start * Collection of socio-demographic data * Collection of consumption data before and during containment * Collection of monitoring data

Conditions

Timeline

Start date
2020-05-01
Primary completion
2020-05-30
Completion
2020-08-01
First posted
2020-05-08
Last updated
2020-12-29

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04380714. Inclusion in this directory is not an endorsement.

Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19 (NCT04380714) · Clinical Trials Directory